Neurocrine Biosciences Inc Stock Price, News & Analysis

Neurocrine Biosciences (Nasdaq: NBIX) has initiated a repurchase of approximately $83 million of its 2.25% Convertible Senior Notes due 2024. The aggregate repurchase price is estimated at $110 million based on the closing stock price of $86.91 on November 18, 2020. The transaction is expected to close on December 2, 2020. This strategic buyback aims to potentially enhance shareholder value, but may also impact the market price of the company's common stock.

Neurocrine Biosciences (NBIX) reported Q3 2020 revenues of $258.5 million, a 16.4% increase from $222.1 million in Q3 2019, driven by a 28% rise in INGREZZA sales to $254 million. However, the company faced a GAAP net loss of $57.6 million compared to a profit of $53.8 million in the previous year, largely due to increased R&D expenses. The guidance for combined GAAP R&D and SG&A expenses was raised to between $880 million and $900 million. Despite the challenges, the company expressed confidence in its growth prospects, particularly for INGREZZA and the newly launched ONGENTYS.

Neurocrine Biosciences (Nasdaq: NBIX) announced upcoming presentations at investor conferences. Kevin Gorman, CEO, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 a.m. ET. On November 17, 2020, at 9:40 a.m. ET, Gorman and CFO Matt Abernethy will present at the Jefferies Virtual London Healthcare Conference. Both presentations will be available via webcast on Neurocrine's website, with replays accessible for one month.

Neurocrine focuses on developing treatments for neurological and endocrine disorders.

Neurocrine Biosciences (Nasdaq: NBIX) will report its third-quarter financial results after market close on November 9, 2020. A conference call will follow at 1:30 p.m. PT, 4:30 p.m. ET, to discuss the results and provide updates. Participants can access the call at 877-830-2596 (US) or 785-424-1744 (International) with conference ID: NBIX. The event will be available for replay on the company's website for approximately one month. Neurocrine specializes in developing treatments for neurological and psychiatric disorders.

On September 28, 2020, Neurocrine Biosciences (Nasdaq: NBIX) announced new data on ONGENTYS^® (opicapone) capsules, the first once-daily COMT inhibitor approved by the FDA for Parkinson's disease patients experiencing 'off' episodes. Phase III analyses reveal ONGENTYS significantly reduces overnight 'off' time and motor fluctuations compared to entacapone. This data will be presented at the American Neurological Association 2020 Virtual Meeting. ONGENTYS also shows promise in lowering daily levodopa requirements, enhancing 'on' time without troublesome dyskinesia.

Neurocrine Biosciences has announced the availability of ONGENTYS (opicapone) in 50 mg capsules, the first FDA-approved once-daily COMT inhibitor for Parkinson's disease. Approved on April 24, 2020, ONGENTYS is an add-on treatment for patients experiencing 'off' episodes while on levodopa/carbidopa. Approximately 1 million Americans suffer from Parkinson's, with about 50,000 new diagnoses each year. Clinical studies indicate ONGENTYS significantly reduces 'off' time and increases 'on' time without troublesome dyskinesia, reflecting a commitment to innovative therapies in movement disorders.

Neurocrine Biosciences (NBIX) announced significant results from post-hoc analyses of Phase III studies demonstrating that ONGENTYS (opicapone) capsules effectively reduce "off" time and increase "on" time in Parkinson's disease patients as an add-on to levodopa/carbidopa. ONGENTYS, approved by the FDA in April 2020, showed that 50 mg doses reduced "off" time by over an hour compared to placebo. Additionally, real-world data revealed increased hospitalization rates linked with prolonged motor fluctuations. The data will be showcased at the MDS Virtual Congress 2020.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, at 1:30 p.m. ET. CEO Kevin Gorman and CFO Matt Abernethy will lead the presentation. The event will be webcast live and can be accessed via the company's website. A replay will be available approximately one hour post-event and archived for one month. Neurocrine, based in San Diego, specializes in treatments for neurological, endocrine, and psychiatric disorders, with multiple FDA-approved products in its portfolio.

Neurocrine Biosciences will present data from 30 abstracts on its movement disorder programs at the 2020 Psych Congress and MDS Virtual Congress. Key highlights include findings from Phase III studies of INGREZZA (valbenazine) for tardive dyskinesia, and ONGENTYS (opicapone) for Parkinson's disease. The data demonstrates sustained clinical benefits and safety for patients. The ongoing commitment to improving patient lives is emphasized by Chief Medical Officer Eiry W. Roberts, M.D. These presentations underline Neurocrine's focus on addressing movement disorders and enhancing treatment outcomes.